Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/1998

01-03-1998

Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy

Authors: Avi I. Einzig, Peter H. Wiernik, Scott Wadler, Jerry Kaplan, Laura T. Benson, Laura Tentoramano, Valiant Tan

Published in: Investigational New Drugs | Issue 1/1998

Login to get access
Metadata
Title
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy
Authors
Avi I. Einzig
Peter H. Wiernik
Scott Wadler
Jerry Kaplan
Laura T. Benson
Laura Tentoramano
Valiant Tan
Publication date
01-03-1998
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/1998
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1006004809169

Other articles of this Issue 1/1998

Investigational New Drugs 1/1998 Go to the issue

OriginalPaper

A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion

OriginalPaper

Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies

OriginalPaper

Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma

OriginalPaper

Phase I study of DMP 840 in pediatric patients with refractory solid tumors

OriginalPaper

Phase I clinical study of didemnin B

OriginalPaper

Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits